RVX.TO - Resverlogix Corp.

Toronto - Toronto Real Time Price. Currency in CAD

Resverlogix Corp.

4820 Richard Road SW
Suite 300
Calgary, AB T3E 6L1

Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Mr. Donald J. McCaffreyCo-Founder, Chairman, Pres, CEO & Sec.505.2kN/AN/A
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBVChief Financial Officer281.8kN/AN/A
Dr. Ewelina Kulikowski Ph.D.Chief Scientific Officer250kN/AN/A
Dr. Jan O. Johansson M.D., Ph.D.Sr. VP of Medical Affairs312.17kN/AN/A
Dr. Michael Sweeney M.D.Sr. VP of Clinical Devel.511.56kN/A1961
Sarah ZapotichnyDirector of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Corporate Governance

Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.